[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524828":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":31,"locations":36,"responsibleParty":53,"collaborators":21,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":21,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":21,"enrollmentInfo":66,"targetDuration":21,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":21,"overallStatus":38,"whyStopped":21,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University of Iowa","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Combination of Palbociclib with Pembrolizumab","EXPERIMENTAL","Palbociclib given for 2 weeks following a pre-treatment ultrasound guided biopsy used to establish an immunological baseline of the tumor microenvironment. After the conclusion of palbociclib therapy, a post-treatment biopsy will be performed to assess the impact of palbociclib on the tumor microenvironment; pembrolizumab will be started the same day as the second biopsy. After 2 doses of pembrolizumab, a third (optional) biopsy could be performed.",[13,14],"Drug: Palbociclib","Drug: Pembrolizumab",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Palbociclib","Palbociclib is a CDK4\u002F6 inhibitor.\n\nPalbociclib, 125 mg, (pediatric dose 75mg\u002Fm2 up to 125mg) daily for 21 days out of every 28 days, PO (orally) starting 14 days prior to Pembrolizumab",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Pembrolizumab","Pembrolizumab is a PD-1 blocking antibody.\n\nGiven 14 days following Palbociclib: Pembrolizumab, 200 mg, once every three weeks, intravenously (IV)",[9],[27],{"name":28,"affiliation":29,"role":30},"John Rieth, MD","University of Iowa Hospitals & Clinics","PRINCIPAL_INVESTIGATOR",[32],{"name":28,"role":33,"phone":34,"phoneExt":21,"email":35},"CONTACT","3193561616","john-rieth@uiowa.edu",[37],{"facility":29,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Iowa City","Iowa","52242","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-91.53017,41.66113,{"lat":48,"lon":47},[51],{"name":28,"role":33,"phone":52,"phoneExt":21,"email":35},"(319) 356-1616",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"SPONSOR_INVESTIGATOR","John Rieth","Clinical Professor","100524828","phase-1-palbociclib-and-pembrolizumab-in-sarcoma-100524828",false,"NCT06113809","Palbociclib and Pembrolizumab in Sarcoma","Phase Ib Trial Evaluating the Combination of CDK4 Inhibitor With Immunotherapy in Patients With Sarcoma","Inclusion Criteria\n\nA potential subject must meet all the following inclusion criteria to be eligible to participate in the study:\n\n* Male or female patients aged \\> or = 12 years old\n* ECOG Performance Status of \\\u003C or = 2\n* Any patient with the diagnosis of locally advanced, unresectable or metastatic sarcoma for which PD-1 inhibitors are approved (undifferentiated pleomorphic sarcoma, myxofibrosarcoma, angiosarcoma, pleomorphic rhabdomyosarcoma, pleomorphic liposarcoma, alveolar soft part sarcoma) who have progressed on at least 1 prior line of therapy. Prior immunotherapy treatment is allowed, including prior treatment with a PD-1 inhibitor.\n* Patients with no known CNS disease, except for treated brain metastasis. Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing treatment for dexamethasone (as ascertained by clinical examination and brain imaging) during the screening period. Stable dose of anticonvulsants is allowed. Treatment for brain metastases may include whole brain radiotherapy, radiosurgery, or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to Day 1 will be excluded.\n* Ability to understand and the willingness to sign a written informed consent or assent in case of patients \\\u003C 18 years old.\n\nExclusion Criteria\n\nA potential subject who meets any of the following exclusion criteria is ineligible to participate in the study:\n\n* Lab values in the below ranges:\n* Neutrophil count \\\u003C 1000\u002Fmm3\n* Platelet count \\\u003C 100,000\u002Fmm3L\n* Hemoglobin \\\u003C 9 g\u002FdL (transfusion to meet eligibility allowed)\n* AST\u002FSGOT and ALT\u002FSGPT \\> 3.0x upper limit of normal (ULN) without disease involvement or \\> 5.0x ULN if the transaminase elevation is due to disease involvement\n* Alkaline phosphatase \\> 5.0x ULN without known bony metastases\n* Serum bilirubin \\> 1.5x ULN\n* Serum creatinine \\> 1.5x ULN or 24-hour creatinine clearance \\\u003C 30 mL\u002Fmin per Cockroft- Gault equation\n* Total serum calcium \\\u003C lower limit of normal (LLN) or if calcium is below LLN the corrected calcium for serum albumin is \\> LLN\n* Serum potassium \\\u003C 3.0\n* Serum sodium \\\u003C 130\n* Serum albumin \\\u003C 2.5 g\u002FdL\n* History of myocardial infarction. unstable angina, stroke or transient ischemic attack within 6 months prior to Day 1\n* History or drug induced pneumonitis (both pembrolizumab and palbociclib can cause pneumonitis)\n* Subjects requiring hemodialysis\n* Patients with severe hepatic impairment (Childs-Pugh Class C).\n* Other concurrent severe and\u002For uncontrolled medical conditions in the opinion of the investigator which will preclude participation\n* Pregnancy (positive pregnancy test) or lactation\n* Concomitant use of any other anti-cancer therapy or radiation therapy of the target lesion. Palliative radiation therapy is permitted to non-target lesions.\n* Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent","ALL","12 Years",{"count":67,"type":68},8,"ESTIMATED","INTERVENTIONAL",[71],"PHASE1","This is a single-arm open-label window of opportunity clinical study assessing the impact of pre-treatment with palbociclib in patients with soft tissue sarcomas for which PD-1 inhibitors are approved (includes undifferentiated pleomorphic sarcoma, myxofibrosarcoma, angiosarcoma, pleomorphic rhabdomyosarcoma, pleomorphic liposarcoma, or alveolar soft part sarcoma).",[74],"Sarcoma","2026-05-20",{"date":77,"type":78},"2026-05-22","ACTUAL",{"date":80,"type":78},"2024-02-01",{"date":82,"type":68},"2028-07",{"name":55,"class":6},1]